Regeneron Pharmaceuticals Inc. (REGN) News
Filter REGN News Items
REGN News Results
|Loading, please wait...|
REGN News Highlights
- For REGN, its 30 day story count is now at 56.
- Over the past 28 days, the trend for REGN's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
- DRUG, SNY and EYE are the most mentioned tickers in articles about REGN.
Latest REGN News From Around the Web
Below are the latest news stories about Regeneron Pharmaceuticals Inc that investors may wish to consider to help them evaluate REGN as an investment opportunity.
Kodiak Sciences' (KOD) KS-301 is an anti-VEGF biologic for the treatment of retinal diseases. The crucial product attribute being assessed in the phase 3 trial was the ability to meaningfully extend the treatment interval while showing non-inferior visual acuity gains compared to aflibercept administered every eight weeks. The study failed...
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics
Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.
Disappointing drug trial results have sent Kodiak Sciences and shares of KOD stock plunging more than 80% in today's trading session.
Thinking about trading options or stock in Block, Mercadolibre, Futu, GameStop, or Regeneron Pharmaceuticals?
NEW YORK , Feb. 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SQ, MELI, FUTU, GME, and REGN. Full story available on Benzinga.com
Kodiak Sciences Inc (NASDAQ: KOD ) has announced topline results from its Phase 2b/3 trial evaluating KSI-301 in treatment-naïve subjects with neovascular (wet) age-related macular degeneration. The trial did not meet the primary efficacy endpoint of showing non-inferior visual acuity gains for subjects dosed on extended regimens compared to Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Eylea (aflibercept) given every eight Full story available on Benzinga.com
The company — which still has a quartet of late-stage trials with the drug and more than $700 million in cash — saw its stock continue to drop on Thursday.
What happened Shares of the clinical-stage biotech Kodiak Sciences (NASDAQ: KOD) are down by a hefty 80.3% as of 2:22 p.m. ET Wednesday afternoon. The drugmaker's stock is plunging today in response to its lead product candidate, KSI-301, failing to meet the primary endpoint of a combined phase 2/3 trial as a treatment for wet age-related macular degeneration (wet AMD).
Kodiak Sciences' attempt to improve on Regeneron's blockbuster eye drug backfired on Wednesday — and investors pummeled KOD stock.
Updates from SAGE and Atara (ATRA) are among a few key highlights from the biotech sector during the past week.
The drug, for wet age-related macular degeneration, is designed to require less frequent injections into the eye than Regeneron's Eylea, the standard treatment.